BioResearch Ireland (BRI) announces anti-Streptokinase and oestradiol tests:
This article was originally published in Clinica
Executive Summary
BioResearch Ireland (BRI) has developed an assay for anti- streptokinase antibodies and a saliva test for oestradiol 17-beta. The two-hour, latex-agglutination SK test is intended for use in heart attack patients who may have had streptokinase treatment for previous heart attacks or even a streptococcal infection. Anti-SK antibodies can neutralise therapeutic streptokinase. The oestradiol assay is a two-hour direct, competitive, solid phase enzyme immunoassay. Saliva-based testing makes repetitive sampling in fertility diagnosis and treatment much less unpleasant.
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.